Presently, the surveillance of progression and estimation of prognosis in patients with PCa mainly rely on conventional clinicopathological variables, such as Gleason scores and PSA, which could partly reflect cancer behavior in biology but may not represent the actual status of PCa. This evidence concerns the gene KLK3 and posterior cortical atrophy.